Histone deacetylases and epigenetic therapies of hematological malignancies.
about
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemiaEpigenomics of leukemia: from mechanisms to therapeutic applicationsExploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation AssaysModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesNotch3 overexpression enhances progression and chemoresistance of urothelial carcinoma.Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.DNA methylation, isocitrate dehydrogenase mutation, and survival in gliomaHDAC inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b.Histone deacetylase inhibitors: emerging mechanisms of resistance.Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitorsMetabolism as a key to histone deacetylase inhibition.Vorinostat enhances chemosensitivity to arsenic trioxide in K562 cell line.Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated MalignanciesPreclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaEpigenetic alterations in bladder cancer and their potential clinical implications.Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma.The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cellsThe histone deacetylase inhibitor sodium valproate causes limited transcriptional change in mouse embryonic stem cells but selectively overrides Polycomb-mediated Hoxb silencingThe antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphomaPerspectives on epigenetics and its relevance to adverse drug reactions.Alterations of DNA methylome in human bladder cancer.Autophagy in blood cancers: biological role and therapeutic implications.Epigenetic alterations in osteosarcoma: promising targets.Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.Current and potential epigenetic targets in multiple myeloma.Epigenetic alterations in acute myeloid leukemias.Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C.Chemosensitivity enhancement toward arsenic trioxide by inhibition of histone deacetylase in NB4 cell line.Histone Modifications and Cancer.Caspase-3 and caspase-6 cleave STAT1 in leukemic cellsHistone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer CellsThe role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.Novel α-substituted tropolones promote potent and selective caspase-dependent leukemia cell apoptosis.Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.
P2860
Q26767024-C8634DD0-4287-454D-8735-DF499FCEC090Q26823403-131EB6D5-6CBB-41D2-8B5E-99B5DD4AACD2Q28550025-55E07A16-8A81-44D1-9AE5-0BDFB79451BCQ30570945-A10114D0-B2C6-4F14-B9DD-48D71B86C7B5Q33798364-632FBBC3-FE6E-4F72-A1DD-70B75D26BA00Q34254302-94979692-7F3F-48A7-ACE4-FD1D16D6F012Q34498783-B104B9D2-2D7B-4E80-A3AB-F097B70E2281Q35070712-270A4CFA-D9D6-4872-A065-CFA1876BF938Q35592607-7BD79F7D-E977-4D56-B799-9A47246B5600Q35621123-0E1EB4A7-0085-4237-94E8-D8563A6952C6Q35661981-F4B8EADE-190B-4491-B575-7783C9428F19Q35670963-1BC5E11C-C36B-4338-B416-406ED713A6B5Q35741591-CF826171-4B61-4DC2-8D47-BBD31BFFD801Q35829978-A8DFA756-73B0-4ED8-BD91-FCF16653E272Q35915726-437F1A47-FCF3-465A-A377-5CF36A10F3A3Q36095721-7EC39CA2-5EA9-470F-8EAC-095ED8479002Q36814349-F92C1B9A-96BE-4F4B-8942-F379B0189601Q36926692-85FEA937-5039-48CB-ABBE-EB390405F2FFQ37016577-9BCD6BC2-BB05-4BB5-95C5-73A2AEE186E2Q37160553-1A8F7804-2CF7-432A-87BD-CF26A6B7EFF1Q37333839-F7568997-AFE7-49E9-85BD-77E54377900AQ37439209-40D735FD-0CDD-47EE-BFD1-F359054C6CE7Q37867482-83AB223D-8C77-4D4C-BBC9-A749703C488AQ38131409-33125654-4A97-4417-84A5-65069E0A2E63Q38134372-D6C094EB-0C10-4E8D-80D5-C1DF952CCBB4Q38185555-5C7E4BB3-7481-47C4-B5BE-F00D24A3A671Q38204386-ACFA1A8D-E2AE-4C75-A87F-94411F6B7091Q38210475-4AEB798E-C4D9-4F77-8C12-AD84788E4B83Q38264968-800820C8-B1F6-4E9E-97B6-863C67869A2AQ38655657-B98242BC-14A5-4696-B447-BDD8BE730EE1Q38770298-7D01623F-F885-4B06-B8EE-0115DFD89B3AQ38796064-F3F95721-90BB-4D2C-BB73-989CEC735519Q38997038-C42E3FEE-1AF3-445C-B709-33F055611C95Q39434896-0F661ABF-0545-42F9-828F-DEAC306A5B99Q39610375-A6808E19-D825-4174-AE9A-51B1D9A084BAQ41386062-0CD807E1-F4BD-424F-A67B-D17F88C755C4Q42328146-B9B3094F-46C7-4300-AC4F-7D6A4DE46035Q42459032-51D5B5CE-66D6-4EB5-9C26-3A2970B5AA67Q42742732-6B32AD8F-6220-45B5-B96A-36AFECF6DD02Q42757408-C968AD06-5F57-4BF0-BBF0-FD2BF14C43DB
P2860
Histone deacetylases and epigenetic therapies of hematological malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Histone deacetylases and epigenetic therapies of hematological malignancies.
@en
Histone deacetylases and epigenetic therapies of hematological malignancies.
@nl
type
label
Histone deacetylases and epigenetic therapies of hematological malignancies.
@en
Histone deacetylases and epigenetic therapies of hematological malignancies.
@nl
prefLabel
Histone deacetylases and epigenetic therapies of hematological malignancies.
@en
Histone deacetylases and epigenetic therapies of hematological malignancies.
@nl
P2093
P1476
Histone deacetylases and epigenetic therapies of hematological malignancies.
@en
P2093
Ciro Mercurio
Pier Giuseppe Pelicci
Saverio Minucci
P356
10.1016/J.PHRS.2010.02.010
P577
2010-02-26T00:00:00Z